ICS use maintains RNFL rate

Article

Intranasal corticosteroids (ICS) maintain retinal nerve fibre layer (RNFL) thickness and optic nerve cup to disc ratio among patients with glaucoma or glaucoma suspect.

Intranasal corticosteroids (ICS) maintains retinal nerve fibre layer (RNFL) thickness and optic nerve cup to disc ratio among patients with glaucoma or glaucoma suspect.

Dr Johnson and his team, Neuro-Ophthalmology Unit, Mason Eye Institute, included 170 glaucoma or glaucoma suspect patients in a retrospective study. The rates of change in RNFL thickness and fast optic disc scan data were compared between ICS users and non-ICS users.

The results revealed there were no significant differences in superior, nasal, inferior and temporal RNFL thickness between ICL users and non-users. There was also no significant difference between the groups in horizontal and vertical cup to disc ratio.

Short-term ICS use presented no significant differences in both optic to cup disc ratio and RNFL thickness in glaucoma or glaucoma suspects.

The abstract was recently published in the European Journal of Ophthalmology.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.